Arrowhead Pharmaceuticals Says Phase 3 Study of Plozasiran Met Primary Endpoint

MT Newswires Live09-03

Arrowhead Pharmaceuticals (ARWR) said Monday a phase 3 study of investigational plozasiran in patients with familial chylomicronemia syndrome met its primary endpoint and all multiplicity-controlled key secondary endpoints.

Familial chylomicronemia syndrome is a genetic disease often caused by monogenic mutations, leading to very high triglyceride levels and causing various serious symptoms.

Plozasiran reduced triglycerides by 80% from baseline and lowered the risk of developing acute pancreatitis by 83%, the company said.

Arrowhead plans to file a new drug application with the US Food and Drug Administration by the end of 2024 and also seek regulatory approval from other authorities thereafter.

Price: 23.60, Change: -0.23, Percent Change: -0.97

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2464898827?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-03 17:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2464898827","market":"sg","top_or_hot":-1,"title":"Arrowhead Pharmaceuticals Says Phase 3 Study of Plozasiran Met Primary Endpoint","media":"MT Newswires Live","content":"<html><body><p> Arrowhead Pharmaceuticals (ARWR) said Monday a phase 3 study of investigational plozasiran in patients with familial chylomicronemia syndrome met its primary endpoint and all multiplicity-controlled key secondary endpoints.</p><p>Familial chylomicronemia syndrome is a genetic disease often caused by monogenic mutations, leading to very high triglyceride levels and causing various serious symptoms.</p><p>Plozasiran reduced triglycerides by 80% from baseline and lowered the risk of developing acute pancreatitis by 83%, the company said.</p><p>Arrowhead plans to file a new drug application with the US Food and Drug Administration by the end of 2024 and also seek regulatory approval from other authorities thereafter.</p><p>Price: 23.60, Change: -0.23, Percent Change: -0.97</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arrowhead Pharmaceuticals Says Phase 3 Study of Plozasiran Met Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArrowhead Pharmaceuticals Says Phase 3 Study of Plozasiran Met Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-03 17:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Arrowhead Pharmaceuticals (ARWR) said Monday a phase 3 study of investigational plozasiran in patients with familial chylomicronemia syndrome met its primary endpoint and all multiplicity-controlled ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2464898827","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2464898827","pubTimestamp":1725354949,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arrowhead Pharmaceuticals (ARWR) said Monday a phase 3 study of investigational plozasiran in patients with familial chylomicronemia syndrome met its primary endpoint and all multiplicity-controlled k","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4139":"生物科技","ARWR":"Arrowhead Research Corporation"},"translate_title":"Arrowhead Pharmaceuticals表示Plozasiran的3期研究达到了主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":1},"content_text":"Arrowhead Pharmaceuticals (ARWR) said Monday a phase 3 study of investigational plozasiran in patients with familial chylomicronemia syndrome met its primary endpoint and all multiplicity-controlled key secondary endpoints.Familial chylomicronemia syndrome is a genetic disease often caused by monogenic mutations, leading to very high triglyceride levels and causing various serious symptoms.Plozasiran reduced triglycerides by 80% from baseline and lowered the risk of developing acute pancreatitis by 83%, the company said.Arrowhead plans to file a new drug application with the US Food and Drug Administration by the end of 2024 and also seek regulatory approval from other authorities thereafter.Price: 23.60, Change: -0.23, Percent Change: -0.97","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2464898827"}